Drug Profile
Research programme: anxiety therapeutics - Sherman Biotech
Alternative Names: SB 15Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Sherman Biotech
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Anxiety disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Anxiety-disorders in USA
- 19 Oct 2006 Preclinical trials in Anxiety disorders in USA (unspecified route)